The management of phosphate homoeostasis is a crucial and a challenging task in chronic kidney disease therapy. The disruption of mineral bone metabolism caused by imbalances of phosphate, calcium and parathormone has severe consequences, including serious and prolonged medical problems like bone diseases and cardiovascular complications and reduced life expectancy.
Treatment of phosphate imbalances with pharmaceuticals is conducted by oral administration of tablets, which bind food-derived phosphate in the gastrointestinal tract, thus rendering it unavailable for absorption. To achieve adequate binding capacity, Fresenius Medical Care uses the long-term proven substance calcium acetate as the main effective ingredient in our phosphate binders.
Gaining control on blood potassium levels is a life-saving postulate in therapy of chronic kidney disease. Appropriate dialysis treatment is the key method in the elimination of excess potassium, but additional support can be gained by the administration of a potassium binder, as Sorbisterit® from Fresenius Medical Care.